文献速递乳腺癌

乳腺癌突变特征重建肿瘤历史并预测新辅助化疗反应

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆.
PubMed 文献 · Ann Oncol · 2021-01-06

基于GeparSepto前瞻性新辅助研究405例治疗前样本的全外显子测序,分析11种突变特征(含APOBEC、HRD、错配修复缺陷、年龄及烟草相关)。HR阳性肿瘤中S3(HRD,P<0.001)、S13(APOBEC,P=0.001)及外显子突变率(P=0.002)与病理完全缓解率升高显著相关;S3(HRD,P=0.006)和S4(烟草,P=0.011)与化疗耐药患者无病生存期降低相关。突变特征组成可反映肿瘤基因组历史并预测化疗反应及耐药亚组生存。

要点

  • HR阳性乳腺癌中HRD相关S3和APOBEC相关S13突变特征与pCR率升高显著相关
  • HRD相关S3和烟草相关S4突变特征与化疗耐药患者无病生存期降低相关
  • 突变特征组成有望识别新辅助化疗高反应及耐药亚组,需进一步验证

核心结论

  • 肿瘤突变特征组成可反映个体基因组历史,并可能预测新辅助化疗反应及耐药肿瘤的无病生存。

研究设计与样本

  • 前瞻性多中心GeparSepto研究,对405例治疗前乳腺癌样本行全外显子测序,分析11种突变特征。

主要发现

  • HR阴性 vs HR阳性肿瘤间突变特征存在显著差异,并与年龄、Ki-67及免疫参数相关。
  • HR阳性肿瘤中S3(HRD,P<0.001)、S13(APOBEC,P=0.001)及外显子突变率(P=0.002)与病理完全缓解率升高显著相关。
  • S3(HRD,P=0.006)和S4(烟草,P=0.011)与化疗耐药患者无病生存期降低相关。

关键数值与推荐

  • HR阳性肿瘤中S3(HRD,P<0.001)和S13(APOBEC,P=0.001)及外显子突变率(P=0.002)与pCR升高显著相关。
  • S3(HRD,P=0.006)和S4(烟草,P=0.011)与化疗耐药患者无病生存期降低相关。

临床怎么用

  • 突变特征分析或可辅助识别新辅助化疗高反应及耐药亚组,但需额外验证后方可用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or age-related DNA alterations, among others, to generate the specific mutational landscape of each individual tumor. The signatures of these mutational processes can be identified in large genomic datasets. We investigated the hypothesis that genomic patterns of mutational signatures are associated with the clinical behavior of breast cancer, in particular chemotherapy response and survival, with a particular focus on therapy-resistant disease. PATIENTS AND METHODS: Whole exome sequencing was carried out in 405 pretherapeutic samples from the prospective neoadjuvant multicenter GeparSepto study. We analyzed 11 mutational signatures including biological processes such as APOBEC-mutagenesis, homologous recombination deficiency (HRD), mismatch repair deficiency and also age-related or tobacco-induced alterations. RESULTS: Different subgroups of breast carcinomas were defined mainly by differences in HRD-related and APOBEC-related mutational signatures and significant differences between hormone-receptor (HR)-negative and HR-positive tumors as well as correlations with age, Ki-67 and immunological parameters were observed. We could identify mutational processes that were linked to increased pathological complete response rates to neoadjuvant chemotherapy with high significance. In univariate analyses for HR-positive tumors signatures, S3 (HRD, P < 0.001) and S13 (APOBEC, P = 0.001) as well as exonic mutation rate (P = 0.002) were significantly correlated with increased pathological complete response rates. The signatures S3 (HRD, P = 0.006) and S4 (tobacco, P = 0.011) were prognostic for reduced disease-free survival of patients with chemotherapy-resistant tumors. CONCLUSION: The results of this investigation suggest that the clinical behavior of a tumor, in particular, response to neoadjuvant chemotherapy and disease-free survival of therapy-resistant tumors, could be predicted by the composition of mutational signatures as an indicator of the individual genomic history of a tumor. After additional validations, mutational signatures might be used to identify tumors with an increased response rate to neoadjuvant chemotherapy and to define therapy-resistant subgroups for future therapeutic interventions.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Denkert C, Untch M, Benz S, et al. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆. Ann Oncol. 2021. PMID: 33418062. doi:10.1016/j.annonc.2020.12.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。